Low C/EBP-β expression is observed in the blast crisis stage of chronic myelogenous leukemia (CML) and is inversely correlated with BCR-ABL tyrosine kinase levels, suggesting that there may be therapeutic potential in restoring its activity in CML-BC (40). Here, CEBPB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.